Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1997-2-11
|
pubmed:abstractText |
The present communication reports on the efficacy of (R)-8-OH-DPAT ((R)-8-hydroxy-2-(di-n-propylamino)tetralin) and (S)-LY-41 ((S)-8-acetyl-2-(di-n-propylamino)tetralin) in displaying the 5-HT1A syndrome and decreasing body temperature after administration of the compound subcutaneously into the gastric ventricle or into the oral cavity in the rat. The dose range eliciting a clear-cut HT1A syndrome and hypothermia after oral cavity administration was 1/10-1/30 that of the gastric ventricle dose range, but 10-30 times higher than the dose range used for subcutaneous administration of both (R)-8-OH-DPAT and (S)-LY-41. Determination of the concentrations of (R)-8-OH-DPAT in plasma and brain tissue confirmed a higher bioavailability after oral cavity than after gastric ventricle administration; plasma and brain tissue concentrations of the drug were found to be approximately 3 times those after 10 mumol/kg-1 orally than after 100 mumol/kg-1 gastroventrically at 15-60 min after administration of (R)-8-OH-DPAT. These findings suggest that the oral cavity may be an important site for drug delivery of 8-OH-DPAT, LY-41 and other compounds with a low gastrointestinal bioavailability.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/8-Hydroxy-2-(di-n-propylamino)tetral...,
http://linkedlifedata.com/resource/pubmed/chemical/8-acetyl-2-(dipropylamino)tetralin,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Receptor Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrahydronaphthalenes
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0022-3573
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
48
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
41-5
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:8722493-8-Hydroxy-2-(di-n-propylamino)tetralin,
pubmed-meshheading:8722493-Absorption,
pubmed-meshheading:8722493-Administration, Oral,
pubmed-meshheading:8722493-Analysis of Variance,
pubmed-meshheading:8722493-Animals,
pubmed-meshheading:8722493-Biological Availability,
pubmed-meshheading:8722493-Body Temperature,
pubmed-meshheading:8722493-Brain,
pubmed-meshheading:8722493-Dose-Response Relationship, Drug,
pubmed-meshheading:8722493-Injections, Subcutaneous,
pubmed-meshheading:8722493-Male,
pubmed-meshheading:8722493-Mouth Mucosa,
pubmed-meshheading:8722493-Rats,
pubmed-meshheading:8722493-Rats, Sprague-Dawley,
pubmed-meshheading:8722493-Serotonin,
pubmed-meshheading:8722493-Serotonin Receptor Agonists,
pubmed-meshheading:8722493-Tetrahydronaphthalenes
|
pubmed:year |
1996
|
pubmed:articleTitle |
Oral cavity absorption of (R)-8-hydroxy-2-(di-n-propylamino)tetralin and (S)-8-acetyl-2-(di-n-propylamino)tetralin in the rat.
|
pubmed:affiliation |
Department of Psychiatry (Ulleråker), Uppsala University, Sweden.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|